Arcturus Therapeutics Holdings (ARCT) FCF Margin (2018 - 2026)

Arcturus Therapeutics Holdings (ARCT) has 9 years of FCF Margin data on file, last reported at 943.28% in Q1 2026.

• Quarterly FCF Margin fell 82322.0% year-over-year to 943.28% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 107.23% (down 4468.0% YoY) and the FY2025 annual result came in at 90.82%, down 5117.0% from the prior year.
• FCF Margin slipped to 943.28% in Q1 2026, from 224.28% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 478.53% in Q2 2023 to a low of 975.4% in Q1 2022.
• A 5-year average of 148.9% and a median of 61.11% in 2024 frame the typical range for FCF Margin.
• Annual changes were most pronounced in 2022 — FCF Margin surged 153201 bps — and 2026, when it plunged 82322 bps.
• Tracing ARCT's FCF Margin over 5 years: stood at 102.07% in 2022, then plunged by 105 bps to 4.87% in 2023, then surged by 74 bps to 1.25% in 2024, then plunged by 17879 bps to 224.28% in 2025, then sank by 321 bps to 943.28% in 2026.
• The last three FCF Margin figures came in at 943.28% (Q1 2026), 224.28% (Q4 2025), and 101.06% (Q3 2025), per Business Quant data.